Already renowned at European level, Nantes’s health research enters a new dimension with the national launch of the radiopharmaceutical network “Isotop4Life”, presented at the Symposium européen de radiopharmacie et de radiopharmaceutiques (European Symposium of Radiopharmacy and Radiopharmaceuticals – ESRR) organized in Nantes (26 to 28 April 2012).
Over the years, a number of academic laboratories and ten companies specialized around nuclear health have emerged and developed in Nantes.
These advanced players decided to join forces to coordinate their R&D, remove barriers to innovation through the selection and validation of biomolecules, promote personalized medicine, and favour the transfer of patients while maximizing the quality, security and radiation protection.
Supported by the competitive cluster “Atlanpole Biotherapies,” * these companies* with strong development potential benefit from an innovative ecosystem and dynamic collective thanks to research laboratories of excellence recently certified by the Ministry of Research at the last national assessment.
According to Atlanpole, this desire and ability to work together makes Nantes, the second French city in terms of start-ups in the field of health in France.
“Our real strength is being able to directly transfer products from research to applications for patients,” said Jean-François Gestin, in charge of Isotop-4-Life and Vice President of Atlanpole Biotherapies. Comprising both educational institutions, superior research teams, industrials and doctors, “the unique feature of the radiopharmaceutical industry Isotop-4-Life is to cover the whole process of radiopharmacy,” said the Inserm researcher who is also co-founder of CHELATEC, created in 2000.
“Isotop-4-Life is so far the only structured network in the radiopharmacy sector at a European level and perhaps even globally,” said Jean-François Gestin. The structure of the network, hosted within the competitive cluster Atlanpole Biotherapies, will enable companies and research teams to be globally identifiable, and to respond to requests and tenders in the days to come throughout Europe, Japan and the United States.